Phase Ib trial of ALT-803, an IL-15 superagonist, plus BCG for the treatment of BCG-naive patients with non-muscle-invasive bladder cancer.

被引：11
|
作者：
Rosser, Charles Joel
Nix, Jeffrey
Ferguson, Lydia
Hernandez, Liza
Wong, Hing C.
机构：
[1] Univ Hawaii Canc Ctr, Honolulu, HI USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] Altor BioScience, Miramar, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.510
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
510
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PHASE IB TRIAL OF ALT-803, AN IL-15 SUPERAGONIST, PLUS BACILLUS CALMETTE GUERIN (BCG) FOR THE TREATMENT OF BCG-NAIVE PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
    Rosser, Charles J.
    Nix, Jeffrey
    Ferguson, Lydia
    Wong, Hing C.
    JOURNAL OF UROLOGY, 2017, 197 (04): : E175 - E175
  • [2] Phase Ib trial of ALT-803, an IL-15 superagonist, plus Bacillus Cohnette Guerin (BOG) for the treatment of patients with BCG-naive non-muscle-invasive bladder cancer (NMIBC).
    Rosser, Charles Joel
    Nix, Jeffrey
    Hernandez, Liza
    Rhode, Peter R.
    Wong, Hing C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [3] Re: IL-15 Superagonist NAI in BCG-Unresponsive Non-muscle-invasive Bladder Cancer
    Suderman, Jonathan
    St-Laurent, Marie-Pier
    Black, Peter C.
    EUROPEAN UROLOGY, 2023, 83 (06) : 581 - 581
  • [4] A multicenter clinical trial of intravesical BCG in combination with ALT-803 in patients with BCG-unresponsive non-muscle invasive bladder cancer.
    Chamie, Karim
    Salmasi, Amirali
    Rosser, Charles Joel
    Rock, Amy
    Ferguson, Lydia
    Wong, Hing C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [5] Sequential intravesical gemcitabine and docetaxel in the treatment of BCG-naive patients with non-muscle invasive bladder cancer.
    Thomas, Lewis
    Steinberg, Ryan
    Nepple, Kenneth Gerard
    O'Donnell, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] A study of intravesical bacillus Calmette-Guerin (BCG) in combination with ALT-803 in patients with non-muscle invasive bladder cancer.
    Rosser, Charles Joel
    Chamie, Karim
    Rock, Amy
    Ferguson, Lydia
    Wong, Hing C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [7] Immunogenomic Analysis of Exceptional Responder to ALT-803 (IL-15 Analogue) in BCG Unresponsive Nonmuscle Invasive Bladder Cancer: A Case Series and Review of the Literature
    Huang, Jeffrey
    Shiao, Stephen L.
    Furuya, Hideki
    Rosser, Charles J.
    JOURNAL OF IMMUNOTHERAPY, 2019, 42 (09) : 354 - 358
  • [8] ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential
    Chen, Wujun
    Liu, Ning
    Yuan, Yang
    Zhu, Meng
    Hu, Xiaokun
    Hu, Wenchao
    Wang, Shuai
    Wang, Chao
    Huang, Binghuan
    Xing, Dongming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [9] Tumor burden reduction in an orthotopic non-muscle-invasive bladder cancer model using IL-15 analogue (ALT-803) targeting T regulatory cells
    Gomes, Evan
    Miyake, Makito
    Zhang, Ge
    Goodison, Steve
    Egan, Jack
    Rhode, Peter
    Wong, Hing C.
    Rosser, Charles Joel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [10] First-line maintenance therapy of adult patients with BCG-naive high-risk non-muscle-invasive bladder cancer
    Rexer, Heidrun
    Stenzl, Arnulf
    Ohlmann, Carsten-Henning
    AKTUELLE UROLOGIE, 2023, 54 (04) : 272 - 273
12345